F049 Respect the Dormant Beast: Optimize Your Management of High-risk Cutaneous SCCs
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Approximately 5% of cutaneous SCCs (cSCCs) harbor high-risk features. The rate of nodal metastasis and disease-specific death for cSCCs are 4% and 1.5%, respectively. Identification and management of high-risk cSCCs can be challenging and is a dynamic field. This session will offer tips on diagnosis and management through two parts. Part A will consist of clinical pearls from experts on management of high-risk cSCCs with a focus on prognostics, surgery, radiologic staging and surveillance, and prevention. Part B will consist of a hybrid tumor board with presentations from the experts and will cover gene expression profiling, adjuvant and neoadjuvant therapies, and management of organ transplant recipients.
LEARNING OBJECTIVES
Recognize clinical, histological and molecular features of high-risk cSCCs, and review outcomes and limitations of current staging systems and gene expression profiling.
Outline opportunities to improve management of cSCCs based on tumor risk stratifications and host factors, using field therapy, radiologic and nodal staging, neoadjuvant therapy, and post-operative adjuvant therapy.
Discuss advances in the management of cSCCs in solid organ transplant recipients.
SCHEDULE
8:30 PM
Clinical Pearls: Prognostics
8:42 PM
Clinical Pearls: Surgery
Justin J. Leitenberger, MD, FAAD
8:54 PM
Clinical Pearls: Prevention
Anokhi Jambusaria-Pahlajani, MD, MS, FAAD
9:06 PM
Clinical Pearls: Radiologic Staging and Surveillance
Addison Michael Demer, MD, FAAD
9:30 PM
Tumor Board
Emily S Ruiz, MD, FAAD, Vishal Patel, MD, Ann Silk, MD, MS
SPEAKERS
Javier Cañueto
Addison Michael Demer, MD, FAAD
Anokhi Jambusaria-Pahlajani, MD, MS, FAAD
Justin J. Leitenberger, MD, FAAD
Vishal Patel, MD
Emily S Ruiz, MD, FAAD
Ann Silk, MD, MS
Evan Wuthrick, MD
SPEAKER DISCLOSURES
Javier Cañueto
No financial relationships exist with ineligible companies.
Addison Michael Demer, MD, FAAD
Palvella Therapeutics – Investigator(Grants/Research Funding); Sanofi/Regeneron – Advisory Board(Fees); Triangulate Labs – Consultant (1099 relationship)(Patent royalties or other compensation for Intellectual Property Rights);
Anokhi Jambusaria-Pahlajani, MD, MS, FAAD
Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);
Justin J. Leitenberger, MD, FAAD
No financial relationships exist with ineligible companies.
Vishal Patel, MD
Almirall – Speaker(Honoraria); Gerson Lehrman Group – Consultant(Fees); Regeneron – Speaker(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Speaker(Honoraria);
Emily S Ruiz, MD, FAAD
Almirall – Consultant (1099 relationship)(Fees); Castle Biosciences, Inc – Investigator(Grants/Research Funding); Checkpoint Therapeutics – Consultant (1099 relationship)(Fees); Feldan Therapeutics – Consultant (1099 relationship)(Fees); Merck – Investigator(Grants/Research Funding); Regeneron – Advisory Board(Fees), Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees), Consultant (1099 relationship)(Fees);
Ann Silk, MD, MS
GRAIL, INC – Stockholder Public Company(Stock); Illumina, Inc. – Stockholder Public Company(Stock); Merck – Advisory Board(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria);
Evan Wuthrick, MD
No financial relationships exist with ineligible companies.